Telescope Innovations Corp · CSE:TELI
Telescope Innovations — Investor Presentation (October 2022)
39 slides from Telescope Innovations's investor presentation, October 2022
Slide 1: Fewer Trials. More Discoveries.
FEWER TRIALS. MORE DISCOVERIES.
Slide 2: Disclaimer and forward-looking statements
TELI (CSE) The Presentation is intended for educational and informational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the participants individually. The information is not designed to provide financial, tax planning, acc
Slide 3: Our Company
TELI (CSE) OUR COMPANY TELIF (OTCQB) Telescope Innovations Corp. leverages a unique combination of automation, analytics, and chemical process research, development and manufacturing expertise to develop next-generation technology platforms. We deploy these products, platforms and services to resolv
Slide 4: What We Do
TELI (CSE) WHAT WE DO AUTOMATION PRODUCTS TELIF (OTCQB) Building a foundational set of advanced automation tools • Powerful analytics and software • Self-driving laboratories Our core platform • Accelerated research technology breaks down barriers in process CONTRACT RESEARCH Developing and commerci
Slide 5: Who We Are
TELI (CSE) WHO WE ARE Our award-winning scientific leadership has collectively authored over 450 academic publications TELIF (OTCQB) and 34 patents. PROF. JASON HEIN DR. BARRY SHARPLESS DR. JEFF SHERMAN PALOMA PRIETO SHAD GRUNERT DR. LARS YUNKER CEO SENIOR ADVISOR COO VP, OPERATIONS VP, INNOVATION VP
Slide 6: Our Board of Directors
TELI (CSE) OUR BOARD OF DIRECTORS Our directors bring over 80 years combined experience in building technology companies and TELIF (OTCQB) successfully managing companies in the capital markets. DR. ANDY ROBINSON ROBERT MINTAK ALI PEJMAN PROF. JASON HEIN HENRY DUBINA An experienced scientist with a
Slide 7: Strategic Partners and Clients
TELI (CSE) STRATEGIC PARTNERS AND CLIENTS TELIF (OTCQB) SCIENTIFIC PHARMACEUTICAL MINING CONSULTING GOVERNMENT INSTRUMENTATION COMPANIES COMPANIES ENGINEERING AND ACADEMIA COMPANIES COMPANIES telescopeinnovations.com 7
Slide 8: Products
PRODUCTS TELIF (OTCQB) TELI (CSE)
Slide 9: Products: Robotic automation and machine learning
TELI (CSE) PRODUCTS We combine robotic automation, online analysis, and machine learning to TELIF (OTCQB) guide chemistry decision-making. = Adaptive automation Quality controls Higher quality data Fewer experiments Fewer trials, and measurements required more discoveries & insights Fully automated
Slide 10: DILC: Direct Inject Liquid Chromatography
TELI (CSE) PRODUCTS DILC: DIRECT INJECT LIQUID CHROMATOGRAPHY TM TELIF (OTCQB) A novel TM Process Analytical Technology (PAT) to analyze chemical processes in real time. A game-changing method of visualizing, understanding and characterizing chemical reactions. telescopeinnovations.com 10
Slide 11: DILC funded and developed for Enabling Technologies Consortium
TELI (CSE) PRODUCTS DILC: DIRECT INJECT LIQUID CHROMATOGRAPHY TM TELIF (OTCQB) DILC was funded & developed in TM response to a specific request by Enabling Technologies Consortium (ETC). ETC members include internationally leading pharmaceutical and chemical companies. Several of these companies have
Slide 12: Global Process Analytical Technology Market
TELI (CSE) GLOBAL PROCESS ANALYTICAL TECHNOLOGY (PAT) MARKET* KEY TELIF (OTCQB) ● Massive, increasing R&D spending in the pharmaceutical and biotech sectors DRIVERS ● Need for automation and quality control in pharmaceutical manufacturing $195.5 B 2021 PAT MARKET BREAKDOWN BY TECHNIQUE Pharma & Biot
Slide 13: Products: Accomplishments and Future Growth
TELI (CSE) PRODUCTS ACCOMPLISHMENTS AND FUTURE GROWTH TELIF (OTCQB) Q2 | 2021 Q1 | 2022 Q1 | 2023 Q1 | 2024 Telescope occupies Pfizer contracts Telescope to PROJECTED: PROJECTED: dedicated lab facility in establish proof-of-concept Telescope develops new Telescope begins Vancouver, British platform f
Slide 14: Contract Research
RESEARCH CONTRACT TELIF (OTCQB) TELI (CSE)
Slide 15: Industrial Contract Research
TELI (CSE) INDUSTRIAL CONTRACT RESEARCH We deploy our expertise, technology, and intellectual property through industrial partnerships TELIF (OTCQB) to resolve bottlenecks and inefficiencies in chemical and pharmaceutical manufacturing. CORE COMPETENCIES APPLICATIONS RESULTS Robotics and Material refi
Slide 16: Project Highlight: Automation for Pharmaceutical R&D
TELI (CSE) PROJECT HIGHLIGHT 1 AUTOMATION FOR TELIF (OTCQB) PHARMACEUTICAL R&D Built proof-of-concept robotic workflow in 4 months We completed a feasibility research project funded by Pfizer to build automated solutions for pharmaceutical process development. Identified pathways to accelerate pharmace
Slide 17: Project Highlight: Clean Energy Process Research
TELI (CSE) PROJECT HIGHLIGHT 2 CLEAN ENERGY PROCESS RESEARCH TELIF (OTCQB) We are optimizing lithium refinement technology in partnership with Standard Lithium (SLI). Our improvements enable higher extraction efficiency of low-grade brines to produce battery-quality materials. We are also exploring th
Slide 18: Project Highlight 3: Big Pharma Manufacturing
TELI (CSE) PROJECT HIGHLIGHT 3: BIG PHARMA MANUFACTURING Telescope Innovation helped resolve a critical manufacturing issue for a large pharmaceutical company. TELIF (OTCQB) This is project is subject to strict confidentiality. The client’s identity and project details are not authorized for public r
Slide 19: Global Contract Research Organization Market
TELI (CSE) GLOBAL CONTRACT RESEARCH ORGANIZATION MARKET* TELIF (OTCQB) GLOBAL CRO MARKET SIZE IN BILLIONS USD 2021 CRO MARKET BREAKDOWN $84.9 B Lab services 80 Regulatory Discovery services $2.53 B 60 $53.9 B Early phase development Preclinical Clinical research $6.74 B $2.53 B 40 services 6.7% CAGR
Slide 20: Contract Research: Accomplishments and Future Growth
TELI (CSE) CONTRACT RESEARCH: ACCOMPLISHMENTS AND FUTURE GROWTH TELIF (OTCQB) Q2 | 2022 Q3 | 2022 Q2 | 2023 Globally-leading Telescope granted contract PROJECTED: pharmaceutical company with Natural Resources Expansion of partnership with contracts Telescope to Canada to automate Pfizer, Hatch and St
Slide 21: Intellectual Property Licensing
TELI (CSE) TELIF (OTCQB) INTELLECTUAL PROPERTY LICENSING
Slide 22: IP Licensing
TELI (CSE) IP LICENSING Our intellectual property strategy provides increasing value TELIF (OTCQB) through positive feedback with our contract research activities and product sales. Enabling technology for R&D and manufacturing NEW INTELLECTUAL ● Analytical tools & methods PROPERTY ● Automation prod
Slide 23: Project Highlight: Synthesis of Novel Therapeutics for Mental Health
PROJECT HIGHLIGHT: SYNTHESIS OF NOVEL THERAPEUTICS FOR MENTAL HEALTH Telescope Innovations developed a proprietary synthesis method to produce pharmaceutical-grade psilocybin. We have filed a PCT patent application and entered the national patenting phase in Canada. Telescope’s unique, proprietary ro
Slide 24: Next Generation Compounds
PROJECT HIGHLIGHT: SYNTHESIS OF NOVEL THERAPEUTICS FOR MENTAL HEALTH Our core technology also enabled the discovery of proprietary novel molecules. These new compounds may pave the way for accessing the next generation of psychedelic medicines and other therapeutics. Targeted Increased safety NEXT G
Slide 25: IP Licensing: Accomplishments and Future Growth
TELI (CSE) INTELLECTUAL PROPERTY LICENSING : ACCOMPLISHMENTS AND FUTURE GROWTH TELIF (OTCQB) Q4 | 2021 Q3 | 2022 Filed non-provisional, PCT patent Entered Canadian application on novel manufacturing national phase with methods for psilocybin and related psilocybin synthesis compounds. patent. 2021 2
Slide 26: Business Case & Shareholder Value Proposition
TELI (CSE) TELIF (OTCQB) BUSINESS CASE & SHAREHOLDER VALUE PROPOSITION
Slide 27: Summarizing the Opportunity
TELI (CSE) SUMMARIZING THE OPPORTUNITY 80 years combined experience in building technology companies and TELIF (OTCQB) STRONG BOARD OF navigating capital markets. Advisors include Prof. Barry Sharpless, 2-time DIRECTORS & KEY ADVISORS Nobel Prize winner in chemistry. DYNAMIC, Chemists, engineers, an
Slide 28: Business Model
TELI (CSE) BUSINESS MODEL TELIF (OTCQB) LICENCE OR ONGOING SELL IP REVENUE IN-HOUSE CONTRACT PROTOTYPE RESEARCH DEVELOPMENT WITH PARTNERS MANUFACTURE IP DEVELOPMENT TO AND SELL LICENSE/SELL telescopeinnovations.com 28
Slide 29: Comparables
TELI (CSE) COMPARABLES SMALL COMPANY LARGE COMPANIES TELIF (OTCQB) ENTERPRISE VALUE/EBITDA OVER THE PAST 3 YEARS** 30 Average: 23.6 Develops lab 20 instruments for process and chemical manufacturing 10 USD $3 M 0 Annual Agilent Bruker Danaher Mettler- Perkin Thermofisher Waters revenue Toledo Elmer S
Slide 30: Capitalization
TELI (CSE) CAPITALIZATION TELIF (OTCQB) Telescope Innovations Corp. Capital Structure | September 28, 2022 Price (Ave) Number Shares issued 48,786,070 Stock options $1.31 3,775,000 Warrants $— — Fully Diluted Share Position 52,561,070 Shares held by Directors / Officers - 10,143,741 (21%) telescopein
Slide 31: Estimated 12-Month Use of Funds
TELI (CSE) ESTIMATED 12-MONTH USE OF FUNDS* TELIF (OTCQB) TOTAL EXPENSES OVER NEXT 12 MONTHS ($ CAD) $3,567,075 Cost of products $578,000 Inventory $500,000 Safety testing $78,000 Operating and admin $2,264,075 Professional fees $159,500 Travel $71,500 Office and laboratory expenses $655,000 Corporat
Slide 32: Strategic Milestones
TELI (CSE) STRATEGIC MILESTONES TELIF (OTCQB) ACCOMPLISHED NEXT 12 MONTHS • Launched DILC product, onboarding • Position DILC as industry standard PRODUCTS units in several pharmaceutical technology for chemical process R&D companies • Engaged in >$1M contract research • Leverage and develop new IP
Slide 33: Thank You
THANK YOU Contact: info@telescopeinn.com FEWER TRIALS. MORE DISCOVERIES.
Slide 34: Supplementary Slides
SUPPLEMENTARY SLIDES
Slide 35: Guideline Company Valuations
TELI (CSE) GUIDELINE COMPANY VALUATIONS TELIF (OTCQB) telescopeinnovations.com 35
Slide 36: Guideline Company Financial Comparables
TELI (CSE) GUIDELINE COMPANY FINANCIAL COMPARABLES TELIF (OTCQB) telescopeinnovations.com 36
Slide 37: Products: Traditional R&D versus Telescope automation
TELI (CSE) PRODUCTS Traditional R&D is the “blind” search for new processes and chemicals. Finding specific chemical TELIF (OTCQB) pathways requires labour-intensive trial and error. Telescope Innovations transforms this approach with more efficient tools and techniques. TRIAL 1 ISOLATION ANALYSIS NEG
Slide 38: DILC: Offline to online analysis
TELI (CSE) PRODUCTS DILC: DIRECT INJECT LIQUID CHROMATOGRAPHY TM TELIF (OTCQB) DILC transforms conventional “offline” analysis into a powerful new “online” technology to visualize, understand and characterize chemical reactions in real time. telescopeinnovations.com 38
Slide 39: DILC integrated with Mettler-Toledo AutoChem
TELI (CSE) PRODUCTS DILC: DIRECT INJECT LIQUID CHROMATOGRAPHY TM TELIF (OTCQB) Integrated with Mettler-Toledo TM AutoChem’s industry leading portfolio of lab instrumentation Already deployed by five major global pharmaceutical companies Rapid, real-time sampling frequency for comprehensive reaction p
Telescope Innovations — Investor Presentation (October 2022) on 6ix